Biolinq Incorporated, a health tech company developing advanced biosensors to support metabolic health, has announced the close of a $100 million Series C financing round led by Alpha Wave Ventures, with continued backing from RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital. The funding will help Biolinq pursue regulatory clearance in the U.S. for its first product, a wearable intradermal glucose sensor. This device, designed for continuous monitoring, uses micro-sensors just beneath the skin to track glucose levels and features a color-changing indicator light to give users immediate visual feedback.
Biolinq’s platform aims to simplify access to real-time glucose data while incorporating sleep and activity information into a single wearable. The company is focused on improving metabolic health through its biosensing technology, with future potential for multi-analyte monitoring. CEO Rich Yang emphasized, “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device.” Currently under investigation and not yet FDA-approved, the device targets people living with Type 2 diabetes who do not use insulin. Backers see the platform as a strong entrant into the biosensor space, combining semiconductor technology with user-friendly health tools.
